{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:55:19Z","timestamp":1786496119775,"version":"build-2736575974"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-12666-4","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T22:20:57Z","timestamp":1753741257000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Multi-target drug discovery for rheumatoid arthritis: a comprehensive computational approach using bioactive compounds"],"prefix":"10.1038","volume":"15","author":[{"given":"Pegah","family":"Mansouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardis","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohrab","family":"Najafipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Amin","family":"Kouhpayeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akbar","family":"Farjadfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmaeil","family":"Behmard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"3","key":"12666_CR1","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.autrev.2004.09.002","volume":"4","author":"Y Alamanos","year":"2005","unstructured":"Alamanos, Y. & Drosos, A. A. Epidemiology of adult rheumatoid arthritis. Autoimmun. Rev. 4 (3), 130\u2013136 (2005).","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"12666_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B","volume":"43","author":"AJ MacGregor","year":"2000","unstructured":"MacGregor, A. J. et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 43 (1), 30\u201337 (2000).","journal-title":"Arthritis Rheum."},{"issue":"4","key":"12666_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/RCT.0000000000001176","volume":"45","author":"K Liu","year":"2021","unstructured":"Liu, K. et al. Evaluation of synovitis of hand in patients with rheumatoid arthritis using diffusion kurtosis magnetic resonance imaging: initial findings. J. Comput. Assist. Tomogr. 45 (4), 557\u2013563 (2021).","journal-title":"J. Comput. Assist. Tomogr"},{"issue":"18","key":"12666_CR4","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJM199005033221805","volume":"322","author":"ED Harris Jr","year":"1990","unstructured":"Harris, E. D. Jr Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl. J. Med. 322 (18), 1277\u20131289 (1990).","journal-title":"N Engl. J. Med."},{"issue":"8","key":"12666_CR5","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00198-020-05360-w","volume":"31","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Effects of glucocorticoids on osteoporosis in rheumatoid arthritis: a systematic review and meta-analysis. Osteoporos. Int. 31 (8), 1401\u20131409 (2020).","journal-title":"Osteoporos. Int."},{"issue":"11","key":"12666_CR6","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1136\/ard.2011.151464","volume":"70","author":"JN Hoes","year":"2011","unstructured":"Hoes, J. N. et al. Glucose tolerance, insulin sensitivity and \u03b2-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann. Rheum. Dis. 70 (11), 1887\u20131894 (2011).","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"12666_CR7","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/rheumatology\/kem311","volume":"47","author":"VF Panoulas","year":"2008","unstructured":"Panoulas, V. F. et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatol. (Oxford). 47 (1), 72\u201375 (2008).","journal-title":"Rheumatol. (Oxford)"},{"issue":"5","key":"12666_CR8","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/ki.1987.131","volume":"31","author":"JA Whitworth","year":"1987","unstructured":"Whitworth, J. A. Mechanisms of glucocorticoid-induced hypertension. Kidney Int. 31 (5), 1213\u20131224 (1987).","journal-title":"Kidney Int."},{"issue":"9","key":"12666_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.7326\/0003-4819-114-9-735","volume":"114","author":"JM Piper","year":"1991","unstructured":"Piper, J. M., Ray, W. A., Daugherty, J. R. & Griffin, M. R. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann. Intern. Med. 114 (9), 735\u2013740 (1991).","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"12666_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0169-6009(91)90139-Q","volume":"8","author":"V LoCascio","year":"1990","unstructured":"LoCascio, V. et al. Bone loss in response to long-term glucocorticoid therapy. Bone Min. 8 (1), 39\u201351 (1990).","journal-title":"Bone Min."},{"issue":"8","key":"12666_CR11","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/rheumatology\/keh685","volume":"44","author":"AYN Lim","year":"2005","unstructured":"Lim, A. Y. N., Gaffney, K. & Scott, D. G. I. Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years. Rheumatology 44 (8), 1051\u20131055 (2005).","journal-title":"Rheumatology"},{"issue":"2","key":"12666_CR12","first-page":"104","volume":"2","author":"R Sotoudehmanesh","year":"2010","unstructured":"Sotoudehmanesh, R., Anvari, B., Akhlaghi, M., Shahraeeni, S. & Kolahdoozan, S. Methotrexate hepatotoxicity in patients with rheumatoid arthritis. Middle East. J. Dig. Dis. 2 (2), 104\u2013109 (2010).","journal-title":"Middle East. J. Dig. Dis."},{"issue":"3","key":"12666_CR13","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1159\/000356817","volume":"7","author":"T Tsukada","year":"2013","unstructured":"Tsukada, T., Nakano, T., Miyata, T. & Sasaki, S. Life-Threatening Gastrointestinal mucosal necrosis during methotrexate treatment for rheumatoid arthritis. Case Rep. Gastroenterol. 7 (3), 470\u2013475 (2013).","journal-title":"Case Rep. Gastroenterol."},{"issue":"6","key":"12666_CR14","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/bjd.21826","volume":"187","author":"MN Landis","year":"2022","unstructured":"Landis, M. N. et al. Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase iib, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study. Br. J. Dermatol. 187 (6), 878\u2013887 (2022).","journal-title":"Br. J. Dermatol."},{"key":"12666_CR15","doi-asserted-by":"crossref","unstructured":"Orecchioni, M., Ghosheh, Y., Pramod, A. B. & Ley, K. Corrigendum: macrophage polarization: different gene signatures in M1(LPS+) vs. classically and M2(LPS-) vs. alternatively activated macrophages. Front. Immunol. 11, 234 (2020).","DOI":"10.3389\/fimmu.2020.00234"},{"issue":"5","key":"12666_CR16","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.jaci.2009.04.003","volume":"123","author":"J Louten","year":"2009","unstructured":"Louten, J., Boniface, K. & de Waal Malefyt, R. Development and function of TH17 cells in health and disease. J. Allergy Clin. Immunol. 123 (5), 1004\u20131011 (2009).","journal-title":"J. Allergy Clin. Immunol."},{"key":"12666_CR17","doi-asserted-by":"crossref","unstructured":"Schinocca, C. et al. Role of the IL-23\/IL-17 pathway in rheumatic diseases: an overview. Front. Immunol. 12, 637829 (2021).","DOI":"10.3389\/fimmu.2021.637829"},{"issue":"Suppl 4","key":"12666_CR18","doi-asserted-by":"publisher","first-page":"iv4","DOI":"10.1093\/rheumatology\/keab266","volume":"60","author":"A Najm","year":"2021","unstructured":"Najm, A. & McInnes, I. B. IL-23 orchestrating immune cell activation in arthritis. Rheumatol. (Oxford). 60 (Suppl 4), iv4\u2013iv15 (2021).","journal-title":"Rheumatol. (Oxford)"},{"issue":"2","key":"12666_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/08923973.2019.1610429","volume":"41","author":"N Yuan","year":"2019","unstructured":"Yuan, N., Yu, G., Liu, D., Wang, X. & Zhao, L. An emerging role of interleukin-23 in rheumatoid arthritis. Immunopharmacol. Immunotoxicol. 41 (2), 185\u2013191 (2019).","journal-title":"Immunopharmacol. Immunotoxicol"},{"issue":"1","key":"12666_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13075-022-02777-y","volume":"24","author":"KMC Lee","year":"2022","unstructured":"Lee, K. M. C., Sherlock, J. P. & Hamilton, J. A. The role of Interleukin (IL)-23 in regulating pain in arthritis. Arthritis Res. Therapy. 24 (1), 89 (2022).","journal-title":"Arthritis Res. Therapy"},{"issue":"3","key":"12666_CR21","doi-asserted-by":"publisher","first-page":"102758","DOI":"10.1016\/j.autrev.2021.102758","volume":"20","author":"M-A Boutet","year":"2021","unstructured":"Boutet, M-A. et al. Novel insights into macrophage diversity in rheumatoid arthritis synovium. Autoimmun. Rev. 20 (3), 102758 (2021).","journal-title":"Autoimmun. Rev."},{"key":"12666_CR22","doi-asserted-by":"publisher","first-page":"155742","DOI":"10.1016\/j.cyto.2021.155742","volume":"149","author":"M Jarlborg","year":"2022","unstructured":"Jarlborg, M. & Gabay, C. Systemic effects of IL-6 Blockade in rheumatoid arthritis beyond the joints. Cytokine 149, 155742 (2022).","journal-title":"Cytokine"},{"issue":"5628","key":"12666_CR23","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1126\/science.1083901","volume":"300","author":"MJ Boulanger","year":"2003","unstructured":"Boulanger, M. J., Chow, D. C., Brevnova, E. E. & Garcia, K. C. Hexameric structure and assembly of the interleukin-6\/IL-6 alpha-receptor\/gp130 complex. Science 300 (5628), 2101\u20132104 (2003).","journal-title":"Science"},{"issue":"11","key":"12666_CR24","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.3390\/cells10113017","volume":"10","author":"A-L Mueller","year":"2021","unstructured":"Mueller, A-L. et al. Recent advances in Understanding the pathogenesis of rheumatoid arthritis: new treatment strategies. Cells 10 (11), 3017 (2021).","journal-title":"Cells"},{"key":"12666_CR25","doi-asserted-by":"publisher","first-page":"108078","DOI":"10.1016\/j.intimp.2021.108078","volume":"99","author":"A Singh","year":"2021","unstructured":"Singh, A. et al. Mechanistic insights into the role of B cells in rheumatoid arthritis. Int. Immunopharmacol. 99, 108078 (2021).","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"12666_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1172\/JCI1316","volume":"101","author":"GA Schellekens","year":"1998","unstructured":"Schellekens, G. A., de Jong, B. A., van den Hoogen, F. H., van de Putte, L. B. & van Venrooij, W. J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. 101 (1), 273\u2013281 (1998).","journal-title":"J. Clin. Invest."},{"issue":"4","key":"12666_CR27","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/annrheumdis-2015-208093","volume":"75","author":"A Krishnamurthy","year":"2016","unstructured":"Krishnamurthy, A. et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann. Rheum. Dis. 75 (4), 721\u2013729 (2016).","journal-title":"Ann. Rheum. Dis."},{"issue":"6483","key":"12666_CR28","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1126\/science.aaz9356","volume":"367","author":"L Roug\u00e9","year":"2020","unstructured":"Roug\u00e9, L. et al. Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. Science 367 (6483), 1224\u20131230 (2020).","journal-title":"Science"},{"key":"12666_CR29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/DDDT.S41645","volume":"8","author":"CC Mok","year":"2013","unstructured":"Mok, C. C. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des. Devel Ther. 8, 87\u2013100 (2013).","journal-title":"Drug Des. Devel Ther."},{"issue":"9","key":"12666_CR30","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"SB Cohen","year":"2006","unstructured":"Cohen, S. B. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54 (9), 2793\u20132806 (2006).","journal-title":"Arthritis Rheum."},{"issue":"8","key":"12666_CR31","first-page":"e16921","volume":"13","author":"S Iftikhar","year":"2021","unstructured":"Iftikhar, S., Khokher, W., Gekonde, J., Kesireddy, N. & Mudiyanselage, P. Rituxan-Induced tumor Lysis syndrome in a patient with diffuse large B-Cell lymphoma. Cureus 13 (8), e16921 (2021).","journal-title":"Cureus"},{"key":"12666_CR32","doi-asserted-by":"crossref","unstructured":"Rymarz, A., Matyjek, A., Su\u0142ek-Jak\u00f3bczyk, M., Mosakowska, M. & Niemczyk, S. Impaired kidney function associated with increased risk of side effects in patients with small vessel vasculitis treated with rituximab as an induction therapy. J. Clin. Med. 10(4), 786 (2021).","DOI":"10.3390\/jcm10040786"},{"issue":"1","key":"12666_CR33","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1542\/peds.2009-3395","volume":"126","author":"DS Ardelean","year":"2010","unstructured":"Ardelean, D. S. et al. Severe ulcerative colitis after rituximab therapy. Pediatrics 126 (1), e243\u2013e246 (2010).","journal-title":"Pediatrics"},{"issue":"4","key":"12666_CR34","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/cc11304","volume":"16","author":"PM Kasi","year":"2012","unstructured":"Kasi, P. M., Tawbi, H. A., Oddis, C. V. & Kulkarni, H. S. Clinical review: serious adverse events associated with the use of rituximab - a critical care perspective. Crit. Care. 16 (4), 231 (2012).","journal-title":"Crit. Care"},{"issue":"1","key":"12666_CR35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000509893","volume":"7","author":"ZY Li","year":"2021","unstructured":"Li, Z. Y., Chen, M. & Zhao, M. H. Severe infections following rituximab treatment in antineutrophil cytoplasmic Antibody-Associated vasculitis. Kidney Dis. (Basel). 7 (1), 50\u201356 (2021).","journal-title":"Kidney Dis. (Basel)"},{"key":"12666_CR36","doi-asserted-by":"publisher","first-page":"20150","DOI":"10.1038\/srep20150","volume":"6","author":"Y Kim","year":"2016","unstructured":"Kim, Y. et al. A dual Target-directed agent against Interleukin-6 receptor and tumor necrosis factor \u03b1 ameliorates experimental arthritis. Sci. Rep. 6, 20150 (2016).","journal-title":"Sci. Rep."},{"issue":"8","key":"12666_CR37","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.biotechadv.2015.08.001","volume":"33","author":"AG Atanasov","year":"2015","unstructured":"Atanasov, A. G. et al. Discovery and resupply of Pharmacologically active plant-derived natural products: A review. Biotechnol. Adv. 33 (8), 1582\u20131614 (2015).","journal-title":"Biotechnol. Adv."},{"key":"12666_CR38","doi-asserted-by":"crossref","unstructured":"Ahmad Khan, M. S. & Ahmad, I. in Chapter 1 - Herbal Medicine: Current Trends and Future Prospects. 3\u201313 (eds Ahmad Khan, M. S., Ahmad, I. & Chattopadhyay, D.) (Academic, 2019).","DOI":"10.1016\/B978-0-12-814619-4.00001-X"},{"issue":"3","key":"12666_CR39","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd3078","volume":"9","author":"SM Paul","year":"2010","unstructured":"Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge. Nat. Rev. Drug Discov. 9 (3), 203\u2013214 (2010).","journal-title":"Nat. Rev. Drug Discov"},{"issue":"4","key":"12666_CR40","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2174\/138620712799361825","volume":"15","author":"M Xiang","year":"2012","unstructured":"Xiang, M., Cao, Y., Fan, W., Chen, L. & Mo, Y. Computer-aided drug design: lead discovery and optimization. Comb. Chem. High. Throughput Screen. 15 (4), 328\u2013337 (2012).","journal-title":"Comb. Chem. High. Throughput Screen."},{"issue":"5","key":"12666_CR41","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.drudis.2014.01.006","volume":"19","author":"MD Segall","year":"2014","unstructured":"Segall, M. D. & Barber, C. Addressing toxicity risk when designing and selecting compounds in early drug discovery. Drug Discov Today. 19 (5), 688\u2013693 (2014).","journal-title":"Drug Discov Today"},{"issue":"18","key":"12666_CR42","doi-asserted-by":"publisher","first-page":"8831","DOI":"10.1080\/07391102.2022.2137699","volume":"41","author":"A Dhiman","year":"2023","unstructured":"Dhiman, A. & Purohit, R. Identification of potential mutational hotspots in serratiopeptidase to address its poor pH tolerance issue. J. Biomol. Struct. Dyn. 41 (18), 8831\u20138843 (2023).","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"19","key":"12666_CR43","doi-asserted-by":"publisher","first-page":"9424","DOI":"10.1080\/07391102.2022.2141895","volume":"41","author":"B Sharma","year":"2023","unstructured":"Sharma, B., Bhattacherjee, D., Zyryanov, G. V. & Purohit, R. An insight from computational approach to explore novel, high-affinity phosphodiesterase 10A inhibitors for neurological disorders. J. Biomol. Struct. Dyn. 41 (19), 9424\u20139436 (2023).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"12666_CR44","doi-asserted-by":"publisher","first-page":"138580","DOI":"10.1016\/j.ijbiomac.2024.138580","volume":"287","author":"A Daroch","year":"2025","unstructured":"Daroch, A., Purohit, R. & MDbDMRP A novel molecular descriptor-based computational model to identify drug-miRNA relationships. Int. J. Biol. Macromol. 287, 138580 (2025).","journal-title":"Int. J. Biol. Macromol."},{"issue":"20","key":"12666_CR45","doi-asserted-by":"publisher","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","volume":"62","author":"ST Wrobleski","year":"2019","unstructured":"Wrobleski, S. T. et al. Highly selective Inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165. J. Med. Chem. 62 (20), 8973\u20138995 (2019).","journal-title":"J. Med. Chem."},{"issue":"12","key":"12666_CR46","doi-asserted-by":"publisher","first-page":"e1004586","DOI":"10.1371\/journal.pcbi.1004586","volume":"11","author":"PA Ravindranath","year":"2015","unstructured":"Ravindranath, P. A., Forli, S., Goodsell, D. S., Olson, A. J. & Sanner, M. F. AutoDockFR: advances in Protein-Ligand Docking with explicitly specified binding site flexibility. PLoS Comput. Biol. 11 (12), e1004586 (2015).","journal-title":"PLoS Comput. Biol."},{"issue":"2","key":"12666_CR47","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock vina: improving the speed and accuracy of Docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31 (2), 455\u2013461 (2010).","journal-title":"J. Comput. Chem."},{"issue":"9","key":"12666_CR48","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","volume":"58","author":"DE Pires","year":"2015","unstructured":"Pires, D. E., Blundell, T. L. & Ascher, D. B. PkCSM: predicting small-molecule Pharmacokinetic and toxicity properties using graph-based signatures. J. Med. Chem. 58 (9), 4066\u20134072 (2015).","journal-title":"J. Med. Chem."},{"key":"12666_CR49","unstructured":"Sander, T. Actelion\u2019s Property Explorer (Actelion\u2019s Pharmaceuticals Ltd, 2001)."},{"key":"12666_CR50","unstructured":"The PyMOL Molecular. Graphics System, Version 3.0 Schr\u00f6dinger, LLC."},{"key":"12666_CR51","doi-asserted-by":"publisher","first-page":"108345","DOI":"10.1016\/j.jmgm.2022.108345","volume":"118","author":"E Behmard","year":"2023","unstructured":"Behmard, E. et al. Advanced simulations and screening to repurposing a 3\u00a0C protease inhibitor against the rupintrivir-resistant human norovirus-induced gastroenteritis. J. Mol. Graph. Model. 118, 108345 (2023).","journal-title":"J. Mol. Graph. Model."},{"key":"12666_CR52","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","volume":"1","author":"MJ Abraham","year":"2015","unstructured":"Abraham, M. J. et al. GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1, 19\u201325 (2015).","journal-title":"SoftwareX"},{"key":"12666_CR53","doi-asserted-by":"crossref","unstructured":"Hess, B., van der Spoel, D., Abraham, M. J. & Lindahl, E. On the importance of accurate algorithms for reliable molecular dynamics simulations. (2019).","DOI":"10.26434\/chemrxiv.11474583.v1"},{"issue":"12","key":"12666_CR54","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1021\/acs.jcim.5b00308","volume":"55","author":"MD Smith","year":"2015","unstructured":"Smith, M. D., Rao, J. S., Segelken, E. & Cruz, L. Force-field induced bias in the structure of A\u03b221\u201330: A comparison of OPLS, AMBER, CHARMM, and GROMOS force fields. J. Chem. Inf. Model. 55 (12), 2587\u20132595 (2015).","journal-title":"J. Chem. Inf. Model."},{"issue":"43","key":"12666_CR55","doi-asserted-by":"publisher","first-page":"9954","DOI":"10.1021\/jp003020w","volume":"105","author":"P Mark","year":"2001","unstructured":"Mark, P. & Nilsson, L. Structure and dynamics of the TIP3P, SPC, and SPC\/E water models at 298 K. J. Phys. Chem. A. 105 (43), 9954\u20139960 (2001).","journal-title":"J. Phys. Chem. A"},{"issue":"19","key":"12666_CR56","doi-asserted-by":"publisher","first-page":"8577","DOI":"10.1063\/1.470117","volume":"103","author":"U Essmann","year":"1995","unstructured":"Essmann, U. et al. A smooth particle mesh Ewald method. J. Chem. Phys. 103 (19), 8577\u20138593 (1995).","journal-title":"J. Chem. Phys."},{"issue":"12","key":"12666_CR57","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","volume":"18","author":"B Hess","year":"1997","unstructured":"Hess, B., Bekker, H., Berendsen, H. J. & Fraaije, J. G. LINCS: A linear constraint solver for molecular simulations. J. Comput. Chem. 18 (12), 1463\u20131472 (1997).","journal-title":"J. Comput. Chem."},{"issue":"12","key":"12666_CR58","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1021\/acs.jcim.7b00564","volume":"57","author":"Z Cournia","year":"2017","unstructured":"Cournia, Z., Allen, B. & Sherman, W. Relative binding free energy calculations in drug discovery: recent advances and practical considerations. J. Chem. Inf. Model. 57 (12), 2911\u20132937 (2017).","journal-title":"J. Chem. Inf. Model."},{"issue":"4","key":"12666_CR59","doi-asserted-by":"publisher","first-page":"e0266632","DOI":"10.1371\/journal.pone.0266632","volume":"17","author":"QH Tran","year":"2022","unstructured":"Tran, Q. H. et al. Structure-based 3D-Pharmacophore modeling to discover novel Interleukin 6 inhibitors: an in Silico screening, molecular dynamics simulations and binding free energy calculations. PLoS One. 17 (4), e0266632 (2022).","journal-title":"PLoS One"},{"issue":"5","key":"12666_CR60","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1007\/s11030-022-10558-7","volume":"27","author":"QH Tran","year":"2023","unstructured":"Tran, Q. H. et al. Identification of small molecules as potential inhibitors of Interleukin 6: a multi-computational investigation. Mol. Divers. 27 (5), 2315\u20132330 (2023).","journal-title":"Mol. Divers."},{"issue":"5","key":"12666_CR61","doi-asserted-by":"publisher","first-page":"e0215927","DOI":"10.1371\/journal.pone.0215927","volume":"14","author":"C Garc\u00eda-Moreno","year":"2019","unstructured":"Garc\u00eda-Moreno, C., G\u00f3mara, M. J., Bleda, M. J., Sanmart\u00ed, R. & Haro, I. Development of a multiplex assay based on chimeric citrullinated peptides as proof of concept for diagnosis of rheumatoid arthritis. PLoS One. 14 (5), e0215927 (2019).","journal-title":"PLoS One"},{"issue":"25","key":"12666_CR62","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JCW Edwards","year":"2004","unstructured":"Edwards, J. C. W. et al. Efficacy of B-Cell\u2013Targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350 (25), 2572\u20132581 (2004).","journal-title":"N. Engl. J. Med."},{"issue":"11\u201312","key":"12666_CR63","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1177\/13524585231195346","volume":"29","author":"SL Hauser","year":"2023","unstructured":"Hauser, S. L. et al. Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: the ALITHIOS open-label extension. Mult Scler. 29 (11\u201312), 1452\u20131464 (2023).","journal-title":"Mult Scler."},{"key":"12666_CR64","doi-asserted-by":"publisher","first-page":"1199799","DOI":"10.3389\/fchem.2023.1199799","volume":"11","author":"D Li","year":"2023","unstructured":"Li, D., Huang, Z., Xu, X. & Li, Y. Promising derivatives of Rutaecarpine with diverse Pharmacological activities. Front. Chem. 11, 1199799 (2023).","journal-title":"Front. Chem."},{"issue":"9","key":"12666_CR65","doi-asserted-by":"publisher","first-page":"e0310364","DOI":"10.1371\/journal.pone.0310364","volume":"19","author":"MSS Shimu","year":"2024","unstructured":"Shimu, M. S. S. Computational screening and molecular Docking of compounds from traditional Chinese medicine (TCM) by targeting DNA topoisomerase I to design potential anticancer drugs. PLoS One. 19 (9), e0310364 (2024).","journal-title":"PLoS One"},{"issue":"4","key":"12666_CR66","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/aps.2015.167","volume":"37","author":"X Nie","year":"2016","unstructured":"Nie, X. et al. Rutaecarpine ameliorates hyperlipidemia and hyperglycemia in fat-fed, streptozotocin-treated rats via regulating the IRS-1\/PI3K\/Akt and AMPK\/ACC2 signaling pathways. Acta Pharmacol. Sin. 37 (4), 483\u2013496 (2016).","journal-title":"Acta Pharmacol. Sin."},{"key":"12666_CR67","doi-asserted-by":"crossref","unstructured":"Wan, J. et al. Rutaecarpine ameliorates osteoarthritis by inhibiting PI3K\/AKT\/NF\u2011\u03baB and MAPK signalling transduction through integrin \u03b1V\u03b23. Int. J. Mol. Med. 52(4), 97 (2023).","DOI":"10.3892\/ijmm.2023.5300"},{"key":"12666_CR68","doi-asserted-by":"publisher","first-page":"106000","DOI":"10.1016\/j.phrs.2021.106000","volume":"175","author":"B Guo","year":"2022","unstructured":"Guo, B. et al. Elucidation of the anti-inflammatory mechanism of Er Miao San by integrative approach of network Pharmacology and experimental verification. Pharmacol. Res. 175, 106000 (2022).","journal-title":"Pharmacol. Res."},{"key":"12666_CR69","doi-asserted-by":"publisher","first-page":"114251","DOI":"10.1016\/j.biopha.2023.114251","volume":"159","author":"MAH Borges","year":"2023","unstructured":"Borges, M. A. H., Passos, F. R. S., Quintans, J. S. S. & Azeredo, F. J. Hecogenin and its derivates: A Pharmacology review. Biomed. Pharmacother. 159, 114251 (2023).","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"12666_CR70","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ejphar.2012.02.043","volume":"683","author":"G Santos Cerqueira","year":"2012","unstructured":"Santos Cerqueira, G. et al. Effects of hecogenin and its possible mechanism of action on experimental models of gastric ulcer in mice. Eur. J. Pharmacol. 683 (1), 260\u2013269 (2012).","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"12666_CR71","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/08923973.2017.1405439","volume":"40","author":"DK Ingawale","year":"2018","unstructured":"Ingawale, D. K. & Patel, S. S. Hecogenin exhibits anti-arthritic activity in rats through suppression of pro-inflammatory cytokines in complete freund\u2019s adjuvant-induced arthritis. Immunopharmacol. Immunotoxicol. 40 (1), 59\u201371 (2018).","journal-title":"Immunopharmacol. Immunotoxicol"},{"key":"12666_CR72","doi-asserted-by":"publisher","first-page":"118741","DOI":"10.1016\/j.jep.2024.118741","volume":"336","author":"Y Zhan","year":"2025","unstructured":"Zhan, Y., Huang, J., Tang, X., Du, B. & Yang, B. Semen strychni pulveratum and vomicine alleviate neuroinflammation in amyotrophic lateral sclerosis through cGAS-STING-TBK1 pathway. J. Ethnopharmacol. 336, 118741 (2025).","journal-title":"J. Ethnopharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12666-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12666-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12666-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:57:04Z","timestamp":1757314624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12666-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12666"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-12666-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27516"}}